Soleus Capital Management L.P. Makes New $28.94 Million Investment in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Soleus Capital Management L.P. purchased a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,276,000 shares of the life sciences company's stock, valued at approximately $28,940,000. Integra LifeSciences comprises approximately 1.8% of Soleus Capital Management L.P.'s investment portfolio, making the stock its 17th largest holding. Soleus Capital Management L.P. owned 1.65% of Integra LifeSciences as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IART. Romano Brothers AND Company bought a new stake in Integra LifeSciences during the fourth quarter valued at about $204,000. Mitsubishi UFJ Asset Management UK Ltd. bought a new stake in Integra LifeSciences during the 4th quarter valued at approximately $204,000. Nisa Investment Advisors LLC boosted its stake in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after purchasing an additional 2,800 shares during the period. Choreo LLC grew its holdings in Integra LifeSciences by 29.9% in the 4th quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock valued at $500,000 after buying an additional 5,123 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Integra LifeSciences in the 4th quarter worth approximately $180,000. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART traded down $0.03 on Thursday, hitting $12.66. The stock had a trading volume of 1,049,225 shares, compared to its average volume of 1,043,312. The company has a market capitalization of $983.83 million, a price-to-earnings ratio of -140.65, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The firm's 50 day moving average price is $17.45 and its 200-day moving average price is $21.54. Integra LifeSciences Holdings Co. has a twelve month low of $11.60 and a twelve month high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $382.65 million for the quarter, compared to the consensus estimate of $381.17 million. During the same period in the prior year, the company posted $0.55 earnings per share. Integra LifeSciences's quarterly revenue was up 3.7% compared to the same quarter last year. On average, equities research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on IART shares. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Wells Fargo & Company cut their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. JMP Securities decreased their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. JPMorgan Chase & Co. lowered their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Finally, Truist Financial reduced their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.